Results 141 to 150 of about 689,537 (284)

Nanomaterials for acute myeloid leukemia therapy: Current progress and future perspectives

Interdisciplinary Medicine, EarlyView.
Infographics of this review introducing the current treatment strategies, types of nanomaterials, and their advantages in AML treatment (Created with BioRender.com, a license purchased, accessed on March 26, 2024). Abstract Acute myeloid leukemia (AML) is a highly aggressive hematologic malignancy characterized by poor prognosis, high relapse rates ...
Jiarui Zhao, Jiaqi Cui, Lixuan Wang, Xinyi Shi, Jiayan Ding, Muhammad Farhan Sohail, Irshad Hussain, Qihui Liu, Fangfang Chen   +8 more
wiley   +1 more source

Comprehensive DSRCT multi‐omics analyses unveil CACNA2D2 as a diagnostic hallmark and super‐enhancer‐driven EWSR1::WT1 signature gene

Cancer Communications, EarlyView.
Florian Henning Geyer, Alina Ritter, Seneca Kinn‐Gurzo, Tobias Faehling, Jing Li, Armin Jarosch, Carine Ngo, Endrit Vinca, Karim Aljakouch, Azhar Orynbek, Shunya Ohmura, Thomas Kirchner, Roland Imle, Laura Romero‐Pérez, Juan Díaz‐Martín, Stefanie Bertram, Enrique de Álava, Clémence Henon, Sophie Postel‐Vilnay, Ana Banito, Martin Sill, Yvonne Versleijen‐Jonkers, Benjamin Friedrich Berthold Mayer, Martin Ebinger, Monika Sparber‐Sauer, Sabine Stegmaier, Daniel Baumhoer, Wolfgang Hartmann, Jeroen Krijgsveld, David Horst, Olivier Delattre, Patrick Joseph Grohar, Thomas Georg Phillip Grünewald, Florencia Cidre‐Aranaz   +33 more
wiley   +1 more source

Illuminating Immunity: A Systematic Review of Immune Cell Autofluorescence

Journal of Biophotonics, EarlyView.
ABSTRACT Immunophenotyping provides valuable prognostic and diagnostic information, but is technically complex and expensive. The assessment of autofluorescence is label‐free and provides complex information on cell identity. However, research on its application to immunophenotyping has been heterogenous.
Aline Knab, Caroline Giardina, Shane T. Grey, Ewa M. Goldys, Jared M. Campbell   +4 more
wiley   +1 more source

Breaking Boundaries: Chronic Diseases and the Frontiers of Immune Microenvironments

Med Research, EarlyView.
ABSTRACT The immune microenvironment includes immune cells, cytokines, extracellular matrix, vesicles, etc. The interactions between these components form a unique local immune microecology. Although immunity serves as the defense against external pathogens, aberrant immune activation often contributes to disease development.
Guoqing Li, Yuxuan Wan, Alan Jiao, Ke Jiang, Gaoyuan Cui, Jinxin Tang, Simin Yu, Zhengang Hu, Songfeng Zhao, Zhenjie Yi, Lifu Long, Yang Yang, Xuehao Cui, Chunrun Qu   +13 more
wiley   +1 more source

Identification of PPFIA3 as a Potential Prognostic and Immune Biomarker Through Pan‐Cancer Analysis

Organ Medicine, EarlyView.
This study reveals a significant increase in the expression of PPFIA3 across various cancers, which is associated with poor prognosis. Notably, in patients receiving anti‐PD‐L1 treatment, high PPFIA3 expression is closely linked to improved survival rates and favorable prognosis, suggesting its potential as a predictive factor for immune checkpoint ...
Xianghong Wang, Rong Lin, Chuanchuan Sun, Niujian Wu, Hongyun Lu   +4 more
wiley   +1 more source

The expression and signalling patterns of CD180 toll like receptor in Chronic Lymphocytic Leukaemia (CLL) [PDF]

, 2019
Chronic lymphocytic leukaemia (CLL) is characterised by a progressive accumulation of mature CD5+CD20+CD23+ lymphocytes. Despite the remarkable progress in our understanding of the immunobiology of CLL, the aetiology of the disease remains unknown.
Sayed, U., Sayed, U.
core  

Resistance mechanisms and clonal dynamics in mantle cell lymphoma treated with sequential BTKi and venetoclax therapy

The Journal of Pathology, EarlyView.
Abstract In recent years, targeted therapies have become the standard of care for refractory/relapsed mantle cell lymphoma (MCL). Although the mutational profile of MCL has been extensively studied, there is a lack of understanding of resistance mechanisms and genetic factors that impact the response to novel treatments.
Tamás László, László Imre Pinczés, Bence Bátai, Luca Varga, Botond Timár, Anita Gulyás, Ilona Tárkányi, Márk Plander, Zsolt Nagy, Péter Rajnics, Miklós Egyed, Zsuzsa Molnár, János Rottek, András Masszi, Péter Tamáska, Róbert Szász, Árpád Illés, Donát Alpár, Ferenc Magyari, Csaba Bödör   +19 more
wiley   +1 more source

Prediction of B/T Subtype and ETV6–RUNX1 Translocation in Pediatric Acute Lymphoblastic Leukemia by Deep Learning Analysis of Giemsa‐Stained Whole Slide Images of Bone Marrow Aspirates

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Accurate determination of B/T‐cell lineage and the presence of the ETV6–RUNX1 translocation is critical for diagnosing acute lymphoblastic leukemia (ALL), as these factors influence treatment decisions and outcomes. However, these diagnostic processes often rely on advanced tools unavailable in low‐resource settings, creating a need
Arkadi Piven, Gil Shamai, Sarah Elitzur, Galit Pinto Berger, Yoav Binenbaum, Ron Kimmel, Ronit Elhasid   +6 more
wiley   +1 more source

Overexpression of an isoform of AML1 in acute leukemia and its potential role in leukemogenesis [PDF]

, 2008
AML1/RUNX1 is a critical transcription factor in hematopoietic cell differentiation and proliferation. From the _AML1_ gene, at least three isoforms, _AML1a_, _AML1b_ and _AML1c_, are produced through alternative splicing.
Chunlin Zhou, Dong-er Zhang, Haiyan Xing, Jianxiang Wang, Min Wang, Qing Rao, Qing Zhang, Xiangrong Liu, Zhen Tian   +8 more
core   +1 more source

Maintenance rituximab following induction R-CHOP chemotherapy in patients with composite or discordant, indolent and aggressive, B-cell non-Hodgkin lymphomas

Haematologica, 2016
Roopesh Kansara, Joseph M. Connors, Kerry J. Savage, Alina S. Gerrie, David W. Scott, Graham W. Slack, Randy D. Gascoyne, Laurie H. Sehn, Diego Villa   +8 more
doaj   +1 more source